164 related articles for article (PubMed ID: 34779234)
21. Frequency, Reasons, and Impact of Premature Ticagrelor Discontinuation in Patients Undergoing Coronary Revascularization in Routine Clinical Practice: Results From the Bern Percutaneous Coronary Intervention Registry.
Zanchin T; Temperli F; Karagiannis A; Zanchin C; Räsänen M; Koskinas KC; Stortecky S; Hunziker L; Praz F; Blöchlinger S; Moro C; Moschovitis A; Seiler C; Billinger M; Heg D; Pilgrim T; Valgimigli M; Windecker S; Räber L
Circ Cardiovasc Interv; 2018 May; 11(5):e006132. PubMed ID: 29748219
[TBL] [Abstract][Full Text] [Related]
22. Clopidogrel versus ticagrelor or prasugrel in patients aged 70 years or older with non-ST-elevation acute coronary syndrome (POPular AGE): the randomised, open-label, non-inferiority trial.
Gimbel M; Qaderdan K; Willemsen L; Hermanides R; Bergmeijer T; de Vrey E; Heestermans T; Tjon Joe Gin M; Waalewijn R; Hofma S; den Hartog F; Jukema W; von Birgelen C; Voskuil M; Kelder J; Deneer V; Ten Berg J
Lancet; 2020 Apr; 395(10233):1374-1381. PubMed ID: 32334703
[TBL] [Abstract][Full Text] [Related]
23. Comparative Efficacy and Safety of Oral P2Y
Navarese EP; Khan SU; Kołodziejczak M; Kubica J; Buccheri S; Cannon CP; Gurbel PA; De Servi S; Budaj A; Bartorelli A; Trabattoni D; Ohman EM; Wallentin L; Roe MT; James S
Circulation; 2020 Jul; 142(2):150-160. PubMed ID: 32468837
[TBL] [Abstract][Full Text] [Related]
24. Ticagrelor or Prasugrel in Patients With Non-ST-Segment Elevation Acute Coronary Syndromes.
Valina C; Neumann FJ; Menichelli M; Mayer K; Wöhrle J; Bernlochner I; Aytekin A; Richardt G; Witzenbichler B; Sibbing D; Cassese S; Angiolillo DJ; Kufner S; Liebetrau C; Hamm CW; Xhepa E; Hapfelmeier A; Sager HB; Wustrow I; Joner M; Trenk D; Laugwitz KL; Schunkert H; Schüpke S; Kastrati A
J Am Coll Cardiol; 2020 Nov; 76(21):2436-2446. PubMed ID: 33213722
[TBL] [Abstract][Full Text] [Related]
25. Prasugrel vs. ticagrelor after acute coronary syndrome: a critical appraisal of the ISAR-REACT 5 trial.
Sulzgruber P; Niessner A
Eur Heart J Cardiovasc Pharmacother; 2020 Sep; 6(5):273-274. PubMed ID: 31865384
[No Abstract] [Full Text] [Related]
26. Prasugrel Versus Ticagrelor in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: a Systematic Review and Meta-analysis of Randomized Trials.
Ray A; Najmi A; Khandelwal G; Jhaj R; Sadasivam B
Cardiovasc Drugs Ther; 2021 Jun; 35(3):561-574. PubMed ID: 32816142
[TBL] [Abstract][Full Text] [Related]
27. Twelve-month clinical outcomes in patients with acute coronary syndrome undergoing complex percutaneous coronary intervention: insights from the ISAR-REACT 5 trial.
Coughlan JJ; Aytekin A; Ndrepepa G; Schüpke S; Bernlochner I; Mayer K; Neumann FJ; Menichelli M; Richardt G; Wöhrle J; Xhepa E; Kufner S; Sager HB; Joner M; Ibrahim T; Fusaro M; Laugwitz KL; Schunkert H; Kastrati A; Cassese S
Eur Heart J Acute Cardiovasc Care; 2021 Dec; 10(10):1117-1124. PubMed ID: 34468709
[TBL] [Abstract][Full Text] [Related]
28. Tailoring Antiplatelet Therapy Intensity to Ischemic and Bleeding Risk.
Baber U; Leisman DE; Cohen DJ; Gibson CM; Henry TD; Dangas G; Moliterno D; Kini A; Krucoff M; Colombo A; Chieffo A; Sartori S; Witzenbichler B; Steg PG; Pocock SJ; Mehran R
Circ Cardiovasc Qual Outcomes; 2019 Jan; 12(1):e004945. PubMed ID: 30606052
[TBL] [Abstract][Full Text] [Related]
29. Fewer gastrointestinal bleeds with ticagrelor and prasugrel compared with clopidogrel in patients with acute coronary syndrome following percutaneous coronary intervention.
Abraham NS; Yang EH; Noseworthy PA; Inselman J; Yao X; Herrin J; Sangaralingham LR; Ngufor C; Shah ND
Aliment Pharmacol Ther; 2020 Aug; 52(4):646-654. PubMed ID: 32657466
[TBL] [Abstract][Full Text] [Related]
30. Ticagrelor versus prasugrel in patients with acute myocardial infarction.
Park S; Kim YG; Ann SH; Park HW; Suh J; Roh JH; Cho YR; Han S; Park GM
Int J Cardiol; 2021 Dec; 344():25-30. PubMed ID: 34619265
[TBL] [Abstract][Full Text] [Related]
31. Secondary prevention of acute coronary events with antiplatelet agents (SPACE-AA): One-year real-world effectiveness and safety cohort study in the French nationwide claims database.
Blin P; Dureau-Pournin C; Benichou J; Bonello L; Dallongeville J; Danchin N; Falissard B; Thomas-Delecourt F; Jové J; Lassalle R; Droz C; Moore N
Atherosclerosis; 2019 Feb; 281():98-106. PubMed ID: 30658197
[TBL] [Abstract][Full Text] [Related]
32. Body mass index and efficacy and safety of ticagrelor versus prasugrel in patients with acute coronary syndromes.
Lahu S; Behnes M; Ndrepepa G; Neumann FJ; Sibbing D; Bernlochner I; Menichelli M; Mayer K; Richardt G; Gewalt S; Angiolillo DJ; Coughlan JJ; Aytekin A; Witzenbichler B; Hochholzer W; Cassese S; Kufner S; Xhepa E; Sager HB; Joner M; Fusaro M; Laugwitz KL; Schunkert H; Schüpke S; Kastrati A; Akin I
Rev Esp Cardiol (Engl Ed); 2022 Sep; 75(9):747-755. PubMed ID: 34961732
[TBL] [Abstract][Full Text] [Related]
33. Ticagrelor versus prasugrel in acute coronary syndrome: sex-specific analysis from the RENAMI Registry.
Al Raisi S; Protty M; Raposeiras-Roubín S; D'Ascenzo F; Abu-Assi E; Ariza-Solé A; Manzano-Fernández S; Templin C; Velicki L; Xanthopoulou I; Cerrato E; Quadri G; Rognoni A; Boccuzzi G; Montabone A; Taha S; Durante A; Gili S; Magnani G; Autelli M; Grosso A; Flores-Blanco P; Varbella F; Cespón-Fernández M; Gallo D; Morbiducci U; Domínguez-Rodríguez A; Cequier Á; Gaita F; Alexopoulos D; Valgimigli M; Íñiguez-Romo A; Kinnaird T
Minerva Cardiol Angiol; 2021 Aug; 69(4):408-416. PubMed ID: 34137238
[TBL] [Abstract][Full Text] [Related]
34. Ticagrelor or Prasugrel in Patients With Acute Coronary Syndrome Undergoing Complex Percutaneous Coronary Intervention.
Coughlan JJ; Aytekin A; Ndrepepa G; Schüpke S; Bernlochner I; Mayer K; Neumann FJ; Menichelli M; Richardt G; Wöhrle J; Witzenbichler B; Gewalt S; Xhepa E; Kufner S; Sager HB; Joner M; Ibrahim T; Fusaro M; Laugwitz KL; Schunkert H; Kastrati A; Cassese S
Circ Cardiovasc Interv; 2021 Jul; 14(7):e010565. PubMed ID: 34130477
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety comparing prasugrel/ticagrelor and clopidogrel in Hong Kong post-acute coronary syndrome patients-A 10-year cohort study.
Lam ASM; Yan BPY; Lee VWY
Clin Cardiol; 2021 Aug; 44(8):1072-1079. PubMed ID: 34041774
[TBL] [Abstract][Full Text] [Related]
36. Comparative effectiveness and safety of prasugrel versus ticagrelor following percutaneous coronary intervention: An observational study.
Belviso N; Aronow HD; Wyss R; Barbour M; Zhang Y; Wen X; Kogut S
Pharmacotherapy; 2021 Jun; 41(6):515-525. PubMed ID: 33932252
[TBL] [Abstract][Full Text] [Related]
37. Safety and Efficacy of Triple Therapy With Ticagrelor or Prasugrel Versus Clopidogrel After Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction.
Gill K; Servati N; Flahive J; Fraielli K
J Cardiovasc Pharmacol Ther; 2021 Nov; 26(6):625-629. PubMed ID: 34236915
[TBL] [Abstract][Full Text] [Related]
38. Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction.
Alexopoulos D; Xanthopoulou I; Gkizas V; Kassimis G; Theodoropoulos KC; Makris G; Koutsogiannis N; Damelou A; Tsigkas G; Davlouros P; Hahalis G
Circ Cardiovasc Interv; 2012 Dec; 5(6):797-804. PubMed ID: 23169985
[TBL] [Abstract][Full Text] [Related]
39. Prasugrel (Efient®) with percutaneous coronary intervention for treating acute coronary syndromes (review of TA182): systematic review and economic analysis.
Greenhalgh J; Bagust A; Boland A; Dwan K; Beale S; Fleeman N; McEntee J; Dundar Y; Richardson M; Fisher M
Health Technol Assess; 2015 Apr; 19(29):1-130. PubMed ID: 25896573
[TBL] [Abstract][Full Text] [Related]
40. [The ISAR-REACT 5 trial: is there a winner between prasugrel and ticagrelor in acute coronary syndromes?].
Ferlini M; Galvani M; Visconti LO
G Ital Cardiol (Rome); 2020 Mar; 21(3):171-174. PubMed ID: 32100728
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
